Aprilbio Co. Ltd.
AprilBio Co., Ltd. develops long-acting type biobetter and antibody biologics. The company develops antibody drugs, double antibodies, long-acting antibody drugs, long-acting protein drugs, and ADC-applied antibodies. It is developing various products for use in the treatment of rare diseases, cancer, male infertility, autoimmune and inflammatory diseases. The company was founded in 2013 and is h… Read more
Market Cap & Net Worth: Aprilbio Co. Ltd. (397030)
Aprilbio Co. Ltd. (KQ:397030) has a market capitalization of $991.89 Million (₩1.45 Trillion) as of March 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #8871 globally and #208 in its home market, demonstrating a 3.75% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aprilbio Co. Ltd.'s stock price ₩63700.00 by its total outstanding shares 22799534 (22.80 Million).
Aprilbio Co. Ltd. Market Cap History: 2022 to 2026
Aprilbio Co. Ltd.'s market capitalization history from 2022 to 2026. Data shows growth from $136.64 Million to $991.89 Million (62.35% CAGR).
Index Memberships
Aprilbio Co. Ltd. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.85 Billion | 0.40% | #53 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.85 Billion | 0.40% | #53 of 1384 |
Weight: Aprilbio Co. Ltd.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aprilbio Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aprilbio Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Aprilbio Co. Ltd.'s market cap is 0.01 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.01x
Aprilbio Co. Ltd.'s market cap is 0.01 times its annual earnings
0.11x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $136.64 Million | $200.00 Million | -$8.96 Billion | 0.68x | N/A |
| 2024 | $252.26 Million | $27.51 Billion | $20.01 Billion | 0.01x | 0.01x |
Competitor Companies of 397030 by Market Capitalization
Companies near Aprilbio Co. Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to Aprilbio Co. Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Aprilbio Co. Ltd. Historical Marketcap From 2022 to 2026
Between 2022 and today, Aprilbio Co. Ltd.'s market cap moved from $136.64 Million to $ 991.89 Million, with a yearly change of 62.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩991.89 Million | +16.03% |
| 2025 | ₩854.86 Million | +238.89% |
| 2024 | ₩252.26 Million | -3.86% |
| 2023 | ₩262.38 Million | +92.02% |
| 2022 | ₩136.64 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Aprilbio Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $991.89 Million USD |
| MoneyControl | $991.89 Million USD |
| MarketWatch | $991.89 Million USD |
| marketcap.company | $991.89 Million USD |
| Reuters | $991.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.